Integra LifeSciences To Spotlight CereLink Intracranial Pressure Monitoring System At The American Association Of Neurological Surgeons Annual Scientific Meeting
Integra LifeSciences To Spotlight CereLink Intracranial Pressure Monitoring System At The American Association Of Neurological Surgeons Annual Scientific Meeting
Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, is pleased to announce that following a successful Q1 2024 U.S. relaunch of its CereLink ICP Monitoring System, the innovative product will be featured at the upcoming AANS Annual Scientific Meeting from May 3 through 6, 2024, in Chicago, Illinois.
全球領先的醫療技術公司Integra LifeSciences Holdings Corporation（納斯達克股票代碼：IART）欣然宣佈，繼2024年第一季度美國成功重啓CereLink ICP監控系統之後，該創新產品將在即將於2024年5月3日至6日在伊利諾伊州芝加哥舉行的AANS年度科學會議上亮相。
The CereLink ICP Monitoring System provides clinicians with uncompromised advanced continuous ICP monitoring, with minimal drift, MR conditional capability, durable, flexible ICP sensors, and advanced data presentation features.1,2
CereLink ICP 監測系統爲臨床醫生提供無與倫比的高級連續 ICP 監測，具有最小的漂移、磁共振條件能力、耐用、靈活的 ICP 傳感器和先進的數據呈現功能。1,2
"The relaunch of the CereLink ICP Monitoring System helps to address the important need for accurate monitoring of intracranial pressure, which is paramount when managing patients with traumatic brain injuries, intracranial hemorrhages, strokes and other neurological conditions," said Mike McBreen, executive vice president and president, Codman Specialty Surgical. "This milestone represents a prime example of the dedication to our mission to innovate treatment pathways to advance patient outcomes and set new standards of care."
科德曼專業外科執行副總裁兼總裁邁克·麥克布雷恩表示：“CereLink ICP監測系統的重新啓動有助於滿足準確監測顱內壓的重要需求，這對於管理創傷性腦損傷、顱內出血、中風和其他神經系統疾病的患者至關重要。”“這個里程碑代表了我們致力於創新治療途徑以改善患者療效和設定新的護理標準的使命，這是一個很好的例子。”
As part of Integra's industry-leading neurosurgical portfolio of products, the CereLink ICP Monitoring System will be highlighted in booth #655 at AANS 2024. To learn more, visit
作爲Integra行業領先的神經外科產品組合的一部分，CereLink ICP監控系統將在2024年AANS的 #655 號展位上重點亮相。要了解更多信息，請訪問
References: 1. CereLink bench test shows (2 stdev) of ±2.2 mmHg over 7 days and 3.8mmHg (4 stdev) over 7 days. 2. CereLink system IFUs
參考文獻：1.CereLink 基準測試顯示，7 天內（2 標準偏差）爲 ±2.2 mmHg，7 天內爲 3.8mmHg（4 標準差）。2.CereLink 系統 IFU